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Abstract 
 
In 2009, uncontained transmission of 
novel H1N1 influenza rapidly became a 
worldwide pandemic and concern.  
Infected pregnant women were 
identified at high risk for H1N1 influenza 
complications that included an 
increased mortality rate that was greater 
than the general population affected by 
the disease.  Major worldwide effort has 
been done over the last year to develop 
a strategy for containment of H1N1 
transmission, disease prevention, and 
vaccination development.  
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Background 
 
During the spring of 2009, headlines 
across the country spread the news that 
an outbreak of influenza-like illness was 
causing significant morbidity and 
mortality to the people of Mexico.  By 
April 2009, two children in the United 
States were diagnosed with a novel 
influenza A (H1N1) and this novel virus 
was found to be the cause of the 
respiratory outbreaks in Mexico. This 
new influenza virus spread quickly 
throughout the world.  On June 11, 
2009, the World Health Organization 
(WHO) announced a worldwide 
pandemic of uncontained community-
level transmission of novel influenza 
H1N1 in numerous regions of the world.   
  
For most healthy people infected with 
influenza H1N1, the disease will be self-
limited.  Several subpopulations 
including pregnant women have been 
identified at high risk for influenza H1N1 
complications.  The designation of 
pregnancy as a high risk condition was 
prompted by a very recent report by the 
Centers for Disease Control and 
Prevention (CDC) published in The 
Lancet 2009. 
 
The Lancet report included all cases of 
infection with H1N1 in pregnant women 
identified through the CCD between 
April 15 and May 18, 2009 as well as 
the deaths associated with this virus 
during the first two months of the 
outbreak.  During the first month of the 
outbreak, 34 cases of confirmed or 
probable cases of H1N1 in pregnant 
women were identified and reported to 
the CDC.  Eleven of these cases were 
admitted to the hospital.  The admission 
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rate for pregnant women infected with 
H1N1 was almost four times higher than 
the admission rate found in the general 
population. The only difference in the 
clinical symptoms between pregnant 
women and the general population was 
a higher incidence of shortness of 
breath.  Also during the first month of 
the outbreak, the reported overall use of 
antiviral therapy increased, but only a 
quarter of these women started antiviral 
therapy in less than 48 hours of 
symptom onset.  By the end of the first 
two months of the outbreak, six 
pregnant women in the United States 
had died of influenza associated 
complications.  Four of the six deaths 
occurred in women who were in their 
third trimester.   All of these women 
developed pneumonia followed by 
respiratory distress syndrome requiring 
mechanical ventilation.    
 
Although the reliance on surveillance 
data and laboratory testing methods to 
determine which cases were reported 
do limit this study, the results strongly 
suggest that pregnant women infected 
with H1N1 are at increased risk as 
compared to the general population.  
Similar adverse outcomes in pregnant 
women can be found in the historical 
observational reports from the prior 
influenza pandemics of 1918 and 1957.  
During both of these pandemics, there 
was a surplus of influenza deaths 
among pregnant women with increased 
incidence of spontaneous abortion and 
preterm labor.  In addition, multiple case 
reports as well as epidemiological 
reports show that pregnant women are 
also at increased risk for pregnancy 
complications during seasonal influenza. 
Thus, prompting the recommendation 
that all pregnant women receive the 
seasonal influenza vaccine. 
Clinical Presentation 
 
Pregnant women infected with influenza 
H1N1 present with classic symptoms of 
acute respiratory illness. These 
symptoms include the typical cough, 
sore throat, rhinorrhea and fever.  Other 
less typical presenting symptoms may 
be body aches, headache, fatigue, 
vomiting and diarrhea.  Many pregnant 
women will have a self-limited disease 
course, but for some, the disease 
progresses rapidly and may be 
complicated by pneumonia, with 
subsequent respiratory distress 
syndrome requiring mechanical 
ventilation.  In less frequent cases, 
these complications have resulted in 
death.   The mortality rate among 
pregnant women is particularly high in 
those affected in the third trimester.   
 
Testing for influenza is not always 
necessary for a pregnant woman with 
fever and respiratory symptoms 
suspicious for flu; especially if she has 
had contact with others with confirmed 
H1N1. Rapid influenza testing is 
available but is poorly sensitive.  
Treatment decisions should not be 
based on a negative rapid test.  
Unfortunately, novel influenza H1N1 
testing remains unavailable at many 
locations, and when it is available it may 
take several days before results are 
available.  Antiviral therapy has been 
shown to be most effective early in the 
disease course; preferably within the 
first 48 hours of symptom onset.  
Because of this, the CDC strongly 
recommends that antiviral therapy begin 
as soon as possible without waiting for 
test results. If necessary, the University 
of Iowa Hygienic Lab will perform PCR 
testing for influenza A and H1N1 
confirmation.  
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Antiviral Treatment 
 
All pregnant women with clinical 
symptoms suspicious for H1N1 should 
have antiviral therapy begun as soon as 
possible without waiting for laboratory 
confirmation. Early antiviral therapy has 
been shown to decrease the severity of 
symptoms, shorten the illness, and 
prevent serious influenza complications.   
Pregnancy should not be considered a 
contraindication to starting antiviral 
therapy. Benefits of these drugs in the 
treatment of H1N1 clearly outweigh the 
risk of antiviral therapy.  The 
neuraminindase inhibitor antiviral 
medication zanamivir (Relenza) and 
oseltamivir (Tamiflu) have both been 
shown to shorten the duration of 
influenza symptoms and the severity of 
the disease process.  Influenza H1N1 is 
resistant to the adamantane antiviral 
medications, amantadine (Symmetrel) 
and rimantadine (Flumadine).   
 
Oseltamivir is the preferred antiviral 
agent for treating influenza H1N1.  In 
contrast to zanamivir, oseltamivir is an 
oral medication and results in systemic 
absorption.  Zanamivir is given by 
inhalation therapy, thereby reducing 
systemic absorption.  Despite these 
differences, if oseltamivir is unavailable 
locally, treatment should be begun with 
zanamivir rather than to delay the onset 
of antiviral treatment.  The 
recommended dosage of oseltamivir is a 
75 mg capsule twice per day for five 
days.  Dosing directions for zanamivir is 
two 5 mg inhalations twice per day for 5 
days.  
 
Chemoprophylaxis 
 
When used to prevent seasonal 
influenza, antiviral drugs have been 
found to be about 70-90% effective 
against susceptible viruses.  Pregnant 
women who have been in close contact 
with individuals who have symptoms of 
influenza-like illness should receive 
post-exposure chemoprophylaxis.  As 
one considers which antiviral to 
prescribe for chemoprophylaxis, 
theoretically the antiviral of choice 
should probably be zanamivir because 
of its limited systemic absorption that is 
targeted specifically to the respiratory 
system.   However, because of the 
inhaled route of administration required 
for zanamivir administration, the side 
effect profile does include possible 
respiratory complications.  Therefore, 
women at known risk for respiratory 
problems should be prescribed 
oseltamivir rather than zanamivir.  The 
recommended duration of treatment for 
chemoprophylaxis for both antivirals is a 
total of 10 days following the last known 
exposure to influenza H1N1.  
Chemoprophylaxis dose for zanamivir is 
two 5 mg inhalations once per day and 
the dose for oseltamivir is a 75 mg 
capsule once per day.  Of note, with 
seasonal influenza, the infectious period 
is considered beginning one day prior to 
the onset of symptoms to up to 7 days 
after the infected person gets sick.  
Therefore, if the contact with the 
infected person occurred more than 7 
days after the onset of symptoms, 
chemoprophylaxis is most likely not 
needed. 
 
Prevention 
 
A vaccine for H1N1 is currently in 
development.  It is expected to be 
available for delivery to the public later 
this fall.  Until this occurs, the best 
methods of prevention are simple steps 
that reduce exposure to the virus.  The 
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CDC general guidelines for prevention 
include the follow steps: (1) Frequent 
hand washing, (2) Minimize contact with 
sick individuals, (3) Have ill persons stay 
home except to seek medical care, (4) 
Cover your mouth when you cough, (5) 
Avoid crowded settings in communities 
having outbreaks of influenza H1N1, (6) 
use facemasks and respirators correctly, 
(7) Limit sharing of toys and anything 
else that has been in an infants mouth.  
After exposure to the infant’s mouth, 
wash these items thoroughly with soap 
and water. 
 
Vaccine 
 
Vaccination has been shown to be the 
most effective way to prevent influenza 
and its complications.  It is unlikely that 
the current seasonal influenza vaccines 
will prevent disease caused by novel 
influenza H1N1.  Studies have been 
done that have tested the seasonal 
influenza vaccine with cross-reactivity 
antibody to novel influenza H1N1.  
Among adults aged 18-64 years, only 
6% to 9% had titers that corresponded 
to a level that is considered high enough 
to protect them against influenza H1N1 
after receiving seasonal vaccine.  In 
those adults aged > 60 years, 33% 
achieved the necessary titer to protect 
them against novel influenza H1N1.  
Specific vaccines are in the 
development process, and are expected 
to be available by mid to late October 
2009.  It remains unclear whether the 
initial supply of vaccine will be enough 
to meet population demand.  Another 
factor that may affect initial supply is the 
number of vaccine doses needed to 
provide adequate protection.  It has 
been established that in children < 9 
years, two doses of seasonal influenza 
vaccine are required to induce immunity 
because young children do not have 
preexisting antibodies.  It follows then 
that an additional dose of novel 
influenza H1N1 may also be required in 
children and young adults in order to 
provide a sufficient level of immunity.  
Studies are currently ongoing to 
determine which age groups may 
require the second dose of vaccine for 
adequate protection.  An additional dose 
required per person may certainly affect 
whether there will be enough initial 
supply to meet demand.  Because of 
these factors, the CDC has identified 
five specific groups that are considered 
to be at high risk for influenza H1N1 and 
its complications.  These groups will be 
targeted for early vaccination. 
 
Recommendations for Vaccine Usage 
 
The Advisory Committee on 
Immunization Practices (ACIP) 
recommends that early vaccination 
should focus on five specific high risk 
groups. These groups include: (1) 
pregnant women, (2) persons who live 
with or provide care for infants aged < 6 
months, (3) health care workers and 
emergency medical services personnel, 
(4) persons aged 6 months - 24 years, 
(5) persons aged 25 - 64 years who 
have medical conditions that put them at 
higher risk for influenza complications.  
In the United States, these five groups 
contain an estimated 159 million people. 
 
If the initial supply fails to meet 
population demand in specific 
geographic areas, the Advisory 
Committee has developed a plan to 
target a subset of the five initial target 
groups.  These subset groups are 
comprised of: (1) pregnant women, (2) 
persons who live with or provide care for 
infants < 6 months, (3) health care and 
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emergency medical services personnel, 
(4) children aged 6 months – 4 years, 
(5) children and adolescents aged 5-18 
years who have medical conditions that 
put them at higher risk for influenza 
related complications.  It is estimated 
that these subset groups would 
comprise approximately 42 million 
people in the United States.  As the 
initial supply increases, decisions to 
expand vaccination outside of the target 
groups should be made based on the 
judgment of state and local health 
officials to best meet the needs of a 
specific region. 
 
Infant Considerations 
 
Infants are at high risk for influenza-
related illness.  It is well known that 
breastfed infants are less susceptible to 
respiratory illness when compared to 
bottle fed infants. Mothers should be 
highly encouraged to breastfeed their 
infants.  The CDC additionally 
recommends that unnecessary formula 
supplementation be eliminated so that 
the infant receives as much maternal 
antibody as is possible.  Ideally, only 
healthy adults should care for infants.  
This includes infant feeding.  The risk for 
transmission of influenza H1N1 through 
breast milk remains unknown.  
However, reports of seasonal flu viremia 
have shown that the risk of virus 
crossing into breast milk is rare.  
Theoretically, this should also be true for 
influenza H1N1.  Both oseltamivir and 
zanamivir are considered to be 
compatible with breastfeeding.  Women 
infected with H1N1 should be 
encouraged to express their milk so that 
healthy adults can bottle feed the infants 
with antibody rich breast milk.   
 
Summary of Current 
Recommendations 
 
1.   Pregnant women are at high risk for 
influenza related complications 
 
2.   Testing for influenza is not always 
necessary for a pregnant woman with 
fever and respiratory symptoms 
suspicious for flu; especially if she has 
had contact with others with confirmed 
H1N1.  Treatment decisions should not 
be based on a negative rapid test.  
Testing should be considered in 
hospitalized patients or if the diagnosis 
is uncertain.  Rapid influenza testing is 
available but is poorly sensitive.  If 
necessary, the PCR testing for H1N1 is 
available thru the University of Iowa 
Hygienic Lab (please see website 
below).  
 
3.   Begin treatment with empiric 
antiviral therapy as soon as possible 
and preferably within the first 48 hours 
of symptom onset.  For women who 
have had symptoms beyond two days 
there is evidence that antiviral therapy 
may still be beneficial.   
 
4.   Oseltamavir is considered the first 
line agent for the treatment of H1N1 
influenza. This drug is administered 
orally and has improved systemic 
absorption when compared to 
zanamivir.  Side effects are fairly 
minimal with the most common reported 
being nausea and vomiting.  
 
5.   Zanamivir is also acceptable for the 
treatment of 2009 H1N1.  The route of 
administration is inhalation and has 
decreased systemic absorption when 
compared to oseltamivir.  Side effects 
include bronchospasm and may lead to 
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respiratory complication in persons with 
underlying respiratory disease 
 
6.   Pregnant women who have been in 
close contact with individuals who have 
symptoms of influenza-like illness 
should receive post-exposure 
chemoprophylaxis.   
 
7.  For chemoprophylaxis in pregnant 
women, a preferred antiviral has not 
been determined.  Zanamivir is 
generally not recommended in persons 
with underlying lung disease such as 
asthma and chronic obstructive 
pulmonary disease. 
 
8.   2009 H1N1 Vaccine should be 
available by mid to late October.  All 
pregnant women should be highly 
encouraged to get the H1N1 vaccine as 
well as the seasonal vaccine. 
 
9.  Preliminary data suggests that older 
children and adults will only require one 
dose of H1N1 vaccine to acquire 
immunity 
 
10. Simultaneous administration of 
inactivated vaccines against seasonal 
and 2009 H1N1 is acceptable if different 
anatomic sites are used. 
 
11. Using data from seasonal influenza 
viremia, the risk of H1N1 virus crossing 
into breast milk is considered rare. The 
CDC highly encourages breastfeeding 
from both healthy and infected mothers 
so that the infant receives as much 
maternal antibody as is possible.   
 
12.  Only healthy adults should be 
caring for infants.  It is recommended 
that infected mothers should express 
their breastmilk and allow a healthy 
adult to bottle feed the infant the 
expressed breastmilk.  
 
13.  Prevention is the key to controlling 
the 2009 H1N1 influenza pandemic.  
The Centers for Disease and Prevention 
Guidelines are as follows: 
 
  a.   Wash hands frequently with 
soap and water or use alcohol-based 
hand cleaner 
 
  b.  Cover your mouth and nose 
with a tissue when coughing or sneezing 
 
  c. Avoid touching your eyes, 
nose and mouth 
 
  d.   People who are sick with an 
influenza-like illness should stay home 
and avoid travel for at least 24 hours 
after fever is gone. 
 
  e. Avoid close contact (within 
about 6 feet) with persons with influenza 
like symptoms 
 
  f. The effectiveness of 
respirators and facemasks in preventing 
transmission of influenza virus is not 
known.  Use of a facemask or respirator 
is of most benefit if used consistently 
when exposed to an ill person. 
 
  g.   Respirators (such as N95 or 
high filtering device) require fitting, 
medical clearance.  Facemasks may be 
considered as an alternative to 
respirators. 
 
 h. Use of respirators of 
facemasks generally are not 
recommended for workers in        
non-healthcare settings for general work 
activities  
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 i.  Ill persons should be placed in 
well ventilated areas when possible and 
placed at least 6 feet away from other 
people. 
 
14.   KEY - Information regarding 2009 
Influenza H1N1 is evolving rapidly.  
Recommendations are frequently 
updated as more information is learned 
regarding 2009 H1N1.  Please refer to 
the websites below to stay updated 
regarding the latest information. 
 
 
Websites 
 
Federal Sites: 
 
- Agency for Healthcare Research and Quality: 
Tools and Resources for Influenza 
Preparedness    
http://www.ahrq.gov/prep/swineflu.htm 
 
- Centers for Disease Control & Prevention 
(CDC):  H1N1 Flu (Swine Flu) 
http://www.cdc.gov/h1n1flu 
 
- National Library of Medicine (NLM) Enviro-
Health Links:  2009 H1N1 Flu 
http://sis.nlm.nih.gov/enviro/swineflu.html 
 
State Sites: 
 
- CDC Public Health Resources:  State Health 
Departments (MMWR): 
http://www.cdc.gov/mmwr/international/relres.ht
ml 
Select state to go to that state’s general health 
department website. 
 
- Iowa Department of Public Health 
www.idph.state.ia.us/ 
Professional Organization: 
 
- American College of Obstetricians and 
Gynecologists (ACOG) 
www.acog.org 
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